SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

Traders are focused on the Iran conflict, Strait of Hormuz shipping risks and reported attacks on energy infrastructure, with concerns about disrupted oil and fuel supply supporting interest in energy stocks. The community is split between those expecting further gains if tensions persist and those warning that diplomacy, easing supply fears or profit-taking could reverse the rally.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to Iran-related tensions and reported threats to oil shipments through the Strait of Hormuz, which have fueled concerns about supply disruptions and supported crude prices. Bulls see further risk from possible escalation and depleted reserves, while bears expect a sharp pullback if negotiations produce a deal or tensions ease.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Hopes for U.S.-Iran de-escalation are weighing on crude prices and UCO, while persistent concerns about Strait of Hormuz disruptions and constrained supply keep some traders bullish. The community is debating whether diplomacy will ease the oil-risk premium or whether renewed conflict will sustain sharp swings.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming Q3 report is the dominant focus, with traders debating whether strong results and raised guidance can clear an already high bar as AI stocks face a broader pullback. Bulls expect continued growth, while skeptics warn that a beat may not prevent selling given the stocks lofty valuation and risk-off sentiment.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,589,443 with 63,351,197,653 in circulation. The last known price of XRP is 1.24455819 USD and is down -0.63 over the last 24 hours. It is currently trading on 1893 active market(s) with $917,900,293.08 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRP is under pressure amid a broader crypto selloff linked by traders to the Binance hack, while Ripples Swell announcements have drawn disappointment over the tokens muted response. The main debate is whether Ripples partnerships, bank charter and RLUSD growth will create demand for XRP, or primarily benefit Ripple and its stablecoin instead.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to a 52-week high has fueled buyout speculationoften centered on Sanofiand hopes for a short squeeze, with traders also pointing to heavy call-option activity. BRIUMVIs commercial growth and forthcoming earnings and subcutaneous data add to the optimism, while some traders doubt a deal is imminent and see the rally as momentum ahead of results.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts strong quarterly results and accelerating Azure growth initially lifted sentiment, but the rally faded as traders weighed heavy AI infrastructure spending and a new bond offering against questions about how quickly that investment will generate returns. Some see Azure demand and positive cash generation as evidence the spending is paying off, while others worry about rising financing needs and broader hyperscaler capex risks.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCelleras ABCL635 antibody for menopausal hot flashes is the dominant focus, with traders discussing its positive Phase 2 results and additional conference data while watching for the still-awaited 12-week durability update. Optimism about the drugs potential and recent analyst coverage contrasts with caution that the available results do not yet establish longer-term benefit or a path through Phase 3.

Cheniere Energy, Inc. engages in liquefied natural gas (LNG) related businesses. It owns and operates LNG terminals, develops, constructs, and operates liquefaction projects near Corpus Christi, Texas, and at the Sabine Pass LNG terminal. The company was founded by Charif Souki in 1983 and is headquartered in Houston, TX.

Cheniere Energy Inc.

Chenieres strong quarterly results, higher full-year cash-flow guidance and dividend increase are driving attention, with traders also citing expansion progress and rising LNG exports. The reaction is broadly bullish, though some are taking profits or cautioning that the sharp run-up may need to cool.

Valero Energy Corp. engages in the manufacture and marketing of transportation fuels and other petrochemical products. It operates through the following business segments: Refining, Ethanol and Renewable Diesel. The Refining segment consists of refining operations, associated marketing activities, and logistics assets that support its refining operations. The Ethanol segment includes its ethanol operations, associated marketing activities, and logistics assets that support its ethanol operations. The Renewable Diesel covers the operations of Diamond Green Diesel Holdings LLC. The company was founded in 1980 and is headquartered in San Antonio, TX.

Valero Energy Corp.

Valero is drawing attention as global refinery disruptions and tight diesel and jet-fuel supplies have widened refining margins, supporting strong earnings and gains across the refining sector. Traders are divided after a sharp pullback: some see the supply squeeze and margins as supportive, while others point to peace and diesel-supply headlines, policy uncertainty, valuation concerns and an analyst downgrade as risks to the rally.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Did ETSY, REPL, GMAB Stocks Surge To 52-Week Highs Today?  

Equity

Investors responded positively to stronger financial performance and progress in medical research. 


Replimune Group Q2 2027 Earnings Call Transcript

Replimune Group (NASDAQ:REPL) reported second-quarter financial results on Wednesday. The transcript from the company's second-quarter earnings call has been provided below.This transcript is brought to you by Benzingaread more...

SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL

SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPLPR NewswireNEW...

REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky

REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit...

REPL Deadline Alert: SueWallSt Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026

REPL Deadline Alert: SueWallSt Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026 REPL Deadline Alert: SueWallSt Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026PR NewswireNEW YORK, Sept. 24...

REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm

REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the FirmPR NewswireNEW YORK, Sept. 23, 2026...

REPL Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending October 5, 2026 Lead Plaintiff Deadline for Information About Recovering Their Losses

REPL Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending October 5, 2026 Lead Plaintiff Deadline for Information About Recovering Their Losses REPL Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending October 5, 2026 Lead Plaintiff...

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallStPR NewswireNEW YORK, Sept. 17, 2026 A chronology of...

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>Etsy shares hit a three-year high of $94.49 after Q3 revenue rose 11%.&nbsp;</li><li>REPL stock climbed to a nearly two-year high as its new melanoma treatment gained early traction.&nbsp;</li><li>Genmab hit a record high after a cancer drug combination cut death risk by 50% in a late-stage trial.&nbsp;</li></ul><p>Etsy Inc. (ETSY), Replimune Group (REPL) and Genmab A/S (GMAB) stock hit fresh highs on Wednesday as stronger-than-expected earnings, early commercial traction for a newly launched treatment and positive late-stage cancer trial results fueled investor optimism, highlighting how company-specific catalysts are driving gains across consumer and biotechnology stocks.&nbsp;</p><p>Genmab and Replimune stocks surged 28% and 23%, respectively, while Etsy stock gained 5%.&nbsp;</p><h2 class="st-heading-2">Etsy Beats Earnings Estimates As Marketplace Trends Improve</h2><p><a href="https://stocktwits.com/symbol/ETSY">Etsy stock</a> reached a three-year high of $94.49 after the company reported an 11% year-over-year&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/etsy-stock-hits-over-3-year-highs-q3-revenue-jumps-11-cfo-to-depart-in-2027/cZU91ZYR9GJ">increase</a> in third-quarter revenue, surpassing analysts' expectations. The online marketplace also recorded its sixth consecutive quarter of improving gross merchandise sales growth, reflecting progress in attracting shoppers.&nbsp;</p><p>Goldman Sachs raised its price target on Etsy to $108 from $89 but kept a ‘Neutral’ rating, suggesting a 17% upside potential from its last closing price. Analyst Eric Sheridan cited better personalized shopping features and more effective marketing. Jefferies also increased its target to $100 from $90.&nbsp;</p><p>On Stocktwits, retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’.&nbsp;</p><h2 class="st-heading-2">Replimune Gains On Early Commercial Progress</h2><p><a href="https://stocktwits.com/symbol/REPL">Replimune stock</a> rose to nearly a two-year high of $16.75 as investors assessed initial demand for TUDRIQEV, the company's newly introduced melanoma treatment. The company said Doctors have started ordering the drug, and the company has enough stock to meet demand for more than a year. Replimune has contacted more than 70% of its first 200 target healthcare accounts to support the drug’s launch.&nbsp;</p><p>Jefferies analyst Roger Song raised his price target to $29 from $24 and retained a ‘Buy’ rating. The firm said that about three weeks after launch, the therapy gained formulary access at about 20 accounts, while more than 15 accounts began prescribing it. Song highlighted adoption by regional centers and the potential for further growth in prescribing activity, repeat use and treatment volume.</p><p>Retail sentiment around the stock remained ‘bullish’.&nbsp;</p><h2 class="st-heading-2">Genmab Advances Following Cancer Trial Results</h2><p><a href="https://stocktwits.com/symbol/GMAB">Genmab stock</a> reached an all-time high of $59.97 after announcing that a pivotal late-stage head and neck cancer study achieved its primary endpoints. The company reported that petosemtamab combined with pembrolizumab reduced the risk of death by 50% compared with pembrolizumab alone in patients with PD-L1-positive head and neck cancer, regardless of HPV status.&nbsp;</p><p>The findings could support upcoming regulatory submissions, potentially bringing the experimental treatment closer to the next stage of development.&nbsp;</p><p>So far this year, ETSY, REPL, and GMAB stocks have gained 65% to 86%.</p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wen-stock-heads-for-best-week-since-june-wendy-s-to-assess-peltz-s-1-4-b-bid-retail-expects-more-offers-to-come/cZUQ349R9Gv">WEN Stock Heads For Best Week Since June: Wendy's To Assess Peltz's $1.4B Bid, Retail Expects 'More Offers To Come'</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

The logo of US e-commerce company Etsy Inc. is displayed on a smartphone in front of abstract background on computer screen. (Photo Illustration by Timon Schneider/SOPA Images/LightRocket via Getty Images)

Etsy Inc. (ETSY), Replimune Group (REPL) and Genmab A/S (GMAB) stock hit fresh highs on Wednesday as stronger-than-expected earnings, early commercial traction for a newly launched treatment and positive late-stage cancer trial results fueled investor opt

Why Did ETSY, REPL, GMAB Stocks Surge To 52-Week Highs Today?

Etsy Inc

Genmab - ADR

$CRWV

$LKNCY

$REPL

$ZETA

$CRWV, $LKNCY, $REPL, and $ZETA are four of the most searched and talked-about stocks among retail investors this morning. Which are you most bullish on? Drop your reasoning in the comments.

Which of these trending stocks are you most bullish on for the next 12 months - $CRWV, $LKNCY, $REPL, or $ZETA?

Current Price	$17.61
Prev Close	$17.39
Open	$17.49
Dividend Yield	0.00%
50-Day Moving Average	$13.58
Beta	0.60
Avg. Volume	2.12M
PE Ratio	-6.04

52-Week High	$18.27
52-Week Low	$1.50
Market Capitalization	$1.67B
EPS (Annual)	-$3.38
Price to Book	8.15
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

REPL Fundamentals